Mads Daugaard - Rakovina Therapeutics CEO President
| RKV Stock | CAD 0.06 0.01 9.09% |
CEO
Mads Daugaard is CEO President of Rakovina Therapeutics
| Address | 999 West Broadway, Vancouver, BC, Canada, V5Z 1K5 |
| Web | https://www.rakovinatherapeutics.com |
Rakovina Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.2673) % which means that it has lost $0.2673 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.6722) %, meaning that it generated substantial loss on money invested by shareholders. Rakovina Therapeutics' management efficiency ratios could be used to measure how well Rakovina Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Rakovina Therapeutics' Net Tangible Assets are fairly stable compared to the past year. Total Current Assets is likely to climb to about 954.6 K in 2024, whereas Non Current Assets Total are likely to drop slightly above 4 M in 2024.Similar Executives
| Found 10 records | CEO Age | ||
| FCPA FCA | Rogers Communications | 59 | |
| John Billowits | Constellation Software | 40 | |
| Mark Miller | Constellation Software | 61 | |
| Dean Burns | Ocumetics Technology Corp | N/A | |
| Michael Konnert | Vizsla Silver Corp | 36 | |
| Damian McKay | Constellation Software | N/A | |
| Jeff Bender | Constellation Software | N/A | |
| Barry Symons | Constellation Software | N/A | |
| Hock Tan | Broadcom | 72 | |
| Robin Poelje | Constellation Software | N/A | |
Management Performance
| Return On Equity | -0.67 | ||||
| Return On Asset | -0.27 |
Rakovina Therapeutics Leadership Team
Elected by the shareholders, the Rakovina Therapeutics' board of directors comprises two types of representatives: Rakovina Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Rakovina. The board's role is to monitor Rakovina Therapeutics' management team and ensure that shareholders' interests are well served. Rakovina Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Rakovina Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Mads Daugaard, CEO President | ||
| John Langlands, Chief Officer | ||
| CBV CA, CFO Secretary | ||
| MBA MBA, Director Development |
Rakovina Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Rakovina Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Rakovina Stock Analysis
When running Rakovina Therapeutics' price analysis, check to measure Rakovina Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Rakovina Therapeutics is operating at the current time. Most of Rakovina Therapeutics' value examination focuses on studying past and present price action to predict the probability of Rakovina Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Rakovina Therapeutics' price. Additionally, you may evaluate how the addition of Rakovina Therapeutics to your portfolios can decrease your overall portfolio volatility.